PT2855456T - Moduladores da via do complemento e usos dos mesmos - Google Patents

Moduladores da via do complemento e usos dos mesmos

Info

Publication number
PT2855456T
PT2855456T PT137290961T PT13729096T PT2855456T PT 2855456 T PT2855456 T PT 2855456T PT 137290961 T PT137290961 T PT 137290961T PT 13729096 T PT13729096 T PT 13729096T PT 2855456 T PT2855456 T PT 2855456T
Authority
PT
Portugal
Prior art keywords
complement pathway
pathway modulators
modulators
complement
pathway
Prior art date
Application number
PT137290961T
Other languages
English (en)
Portuguese (pt)
Inventor
Mainolfi Nello
J Powers James
Michael Adams Christopher
Babu Charles
Ding Jian
Ehara Takeru
Jendza Keith
Ji Nan
Ganesh Karki Rajeshri
Kawanami Toshio
Xue Liang
H Serrano-Wu Michael
Zhang Chun
Paul Capparelli Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2855456(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2855456T publication Critical patent/PT2855456T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT137290961T 2012-05-04 2013-05-03 Moduladores da via do complemento e usos dos mesmos PT2855456T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642798P 2012-05-04 2012-05-04
US201361782820P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PT2855456T true PT2855456T (pt) 2017-07-10

Family

ID=48626502

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137290961T PT2855456T (pt) 2012-05-04 2013-05-03 Moduladores da via do complemento e usos dos mesmos

Country Status (25)

Country Link
EP (1) EP2855456B1 (enExample)
JP (1) JP6180514B2 (enExample)
KR (1) KR20150003903A (enExample)
CN (1) CN104603127B (enExample)
AP (1) AP2014008040A0 (enExample)
AR (1) AR090945A1 (enExample)
AU (1) AU2013255470B2 (enExample)
BR (1) BR112014027359A2 (enExample)
CA (1) CA2872000A1 (enExample)
CL (1) CL2014002919A1 (enExample)
CR (1) CR20140508A (enExample)
EA (1) EA027113B1 (enExample)
ES (1) ES2630079T3 (enExample)
HK (1) HK1206017A1 (enExample)
IL (1) IL235362A0 (enExample)
MX (1) MX2014013428A (enExample)
PE (1) PE20150623A1 (enExample)
PH (1) PH12014502462A1 (enExample)
PL (1) PL2855456T3 (enExample)
PT (1) PT2855456T (enExample)
SG (1) SG11201406973PA (enExample)
TN (1) TN2014000449A1 (enExample)
TW (1) TW201348199A (enExample)
UY (1) UY34781A (enExample)
WO (1) WO2013164802A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6387391B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 眼科疾患の処置に有用な補体因子B阻害剤としての2−(1H−インドール−4−イルメチル)−3H−イミダゾ[4,5−b]ピリジン−6−カルボニトリル誘導体
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP2016535042A (ja) * 2013-10-30 2016-11-10 ノバルティス アーゲー 2−ベンジル−ベンゾイミダゾール補体因子b阻害剤およびその使用
CN103755622A (zh) * 2013-12-25 2014-04-30 华东理工大学 合成4,5,6,7-四氘代吲哚-3-乙酸的方法
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
TWI854164B (zh) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
KR20190036520A (ko) * 2016-06-27 2019-04-04 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
TW202535858A (zh) * 2018-04-06 2025-09-16 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
US20230271951A1 (en) * 2020-04-07 2023-08-31 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
EP4194449A4 (en) 2020-08-07 2024-03-20 Shanghai Meiyue Biotech Development Co., Ltd. Heterocyclic compound, preparation method therefor and use thereof
EP4194451A4 (en) 2020-08-07 2024-07-24 Shanghai Meiyue Biotech Development Co., Ltd. SUPPLEMENT FACTOR B INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF, CORRESPONDING PREPARATION METHOD AND ASSOCIATED USE
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
TWI843416B (zh) 2022-01-26 2024-05-21 大陸商上海美悦生物科技發展有限公司 補體因子b抑制劑的鹽型、晶型及其製備方法和用途
EP4504699A1 (en) * 2022-04-01 2025-02-12 Novartis AG Complement factor b inhibitors and uses thereof
JP2025541667A (ja) 2022-11-11 2025-12-23 シャンハイ イーシェン バイオファーマシューティカル カンパニー リミテッド ピペリジン置換安息香酸系化合物、その医薬組成物および使用
CN120435467A (zh) * 2022-12-31 2025-08-05 珠海联邦制药股份有限公司 补体因子b抑制剂及其药物组合物和应用
WO2025008451A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008453A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB8420919D0 (en) * 1984-08-17 1984-09-19 Beecham Group Plc Compounds
DE19545464A1 (de) * 1995-12-06 1997-06-12 Bayer Ag Benzimidazol-isoindoleninfarbstoffe
KR20070057276A (ko) * 2000-01-17 2007-06-04 데이진 가부시키가이샤 벤즈이미다졸 유도체
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
BRPI0518159A (pt) * 2004-10-08 2008-11-04 Schering Corp antagonistas de receptor de trombina
WO2007034277A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
AU2007271188B2 (en) * 2006-07-03 2012-11-01 Proximagen Limited Indoles as 5-HT6 modulators
JO3265B1 (ar) * 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
CN102264227B (zh) * 2008-12-22 2014-07-23 凯莫森特里克斯股份有限公司 C5aR拮抗剂
MX2011008674A (es) * 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.
EP2447263A1 (en) * 2010-09-27 2012-05-02 Bioprojet Benzazole derivatives as histamine H4 receptor ligands
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators

Also Published As

Publication number Publication date
EA027113B1 (ru) 2017-06-30
WO2013164802A1 (en) 2013-11-07
IL235362A0 (en) 2014-12-31
JP2015515976A (ja) 2015-06-04
AP2014008040A0 (en) 2014-10-31
AU2013255470B2 (en) 2015-09-17
PH12014502462A1 (en) 2014-12-22
CN104603127A (zh) 2015-05-06
UY34781A (es) 2013-12-31
PL2855456T3 (pl) 2017-09-29
JP6180514B2 (ja) 2017-08-16
EA201492023A1 (ru) 2015-03-31
HK1206017A1 (en) 2015-12-31
AU2013255470A1 (en) 2014-11-13
SG11201406973PA (en) 2014-12-30
ES2630079T3 (es) 2017-08-17
CL2014002919A1 (es) 2015-07-03
CR20140508A (es) 2015-03-13
MX2014013428A (es) 2015-02-04
CN104603127B (zh) 2016-10-05
PE20150623A1 (es) 2015-05-17
TW201348199A (zh) 2013-12-01
EP2855456A1 (en) 2015-04-08
EP2855456B1 (en) 2017-03-29
CA2872000A1 (en) 2013-11-07
KR20150003903A (ko) 2015-01-09
BR112014027359A2 (pt) 2017-07-18
AR090945A1 (es) 2014-12-17
TN2014000449A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
IL235362A0 (en) Modulators of the complement system and their use
EP2844247A4 (en) ROR MODULATORS AND ITS USES
IL245733A0 (en) aplnr modulators and their uses
GB2574506B (en) Security devices
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
EP2934342A4 (en) DEVICES AND METHODS OF DISCECTOMY
GEP20237477B (en) Nuclear transport modulators and uses thereof
EP2844259A4 (en) MMR MODULATORS AND USES THEREOF
IL237926A0 (en) Combinations and their uses
PL2745849T3 (pl) Kompozycja polideoksyrybonukleotydów i jej zastosowanie
EP2844260A4 (en) ROR MODULATORS AND ITS USES
PL2909819T3 (pl) Urządzenia zabezpieczające
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
GB201220117D0 (en) Computing devices
SMT201700322T1 (it) Composizione dermoprotettiva e dermoequilibrante
GB201210989D0 (en) Composition and device
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201217715D0 (en) Improvements in swimfeeder devices
GB201213642D0 (en) Security devices
GB201214749D0 (en) Compounds and their uses
AU2012228V (en) GFLEUWHMTN Leucanthemum xsuperbum
GB201203451D0 (en) Thin devices
GB201212028D0 (en) Epit